Nossal Institute for Global Health, Centre for Clinical Research Excellence in Infectious Diseases, University of Melbourne, Carlton, Victoria 3010, Australia.
Vaccine. 2009 Dec 9;27(52):7228-35. doi: 10.1016/j.vaccine.2009.08.112. Epub 2009 Sep 15.
The WHO Initiative for Vaccine Research (IVR) Malaria Vaccine Advisory Committee (MALVAC) provides advice to WHO on priorities in malaria vaccine research and development (R&D). This document summarizes a MALVAC scientific consultation of leading vaccine scientists on priorities in Plasmodium vivax vaccine R&D. The meeting discussed recent advances and key challenges in addressing identified gaps in knowledge. Major areas of discussion included disease burden estimates, clinical disease spectrum definitions, potential target product profiles and immunological and clinical research needed to better inform antigen selection and vaccine design. The need for further development of the human challenge model for P. vivax vaccines and specific considerations for conduct of field trials with P. vivax vaccines was outlined. This report summarizes the discussion and conclusions of the consultation, with recommendations for priority targeted research.
世界卫生组织疫苗研究倡议（IVR）疟疾疫苗咨询委员会（MALVAC）就疟疾疫苗研究与开发（R&D）的优先事项向世卫组织提供建议。本文件总结了 MALVAC 就开发间日疟原虫疫苗的优先事项举行的一次疫苗科学家高级别磋商会议的情况。会议讨论了在解决已确定的知识差距方面的最新进展和主要挑战。讨论的主要领域包括疾病负担估计、临床疾病谱定义、潜在的目标产品特性以及为更好地确定抗原选择和疫苗设计提供信息所需的免疫和临床研究。会议概述了进一步开发用于间日疟原虫疫苗的人体挑战模型的必要性以及开展间日疟原虫疫苗现场试验的具体考虑。本报告总结了磋商会议的讨论和结论，并提出了优先重点研究的建议。
